Duloxetine drug interactions
Pro Research Analysisby 
Searched over 200M research papers
Duloxetine Drug Interactions: A Comprehensive Overview
Introduction to Duloxetine and Its Mechanism of Action
Duloxetine is a balanced serotonin and norepinephrine reuptake inhibitor (SNRI) widely used for treating major depressive disorder (MDD), diabetic peripheral neuropathic pain (DPNP), generalized anxiety disorder, and fibromyalgia 37. Given its extensive use, understanding its drug interactions is crucial for safe and effective therapy.
Duloxetine and Cytochrome P450 Enzyme Interactions
CYP2D6 Inhibition
Duloxetine is metabolized primarily by the cytochrome P450 enzymes CYP2D6 and CYP1A2 47. It is a moderate inhibitor of CYP2D6, which can lead to significant drug-drug interactions (DDIs) with other medications metabolized by this enzyme. For instance, coadministration with desipramine, a CYP2D6 substrate, significantly increases desipramine's area under the curve (AUC) and peak plasma concentration (Cmax) by 122% and 63%, respectively . This suggests a higher risk of adverse effects when duloxetine is combined with other CYP2D6 substrates.
CYP1A2 Inhibition
Duloxetine's interaction with CYP1A2 inhibitors can also be clinically significant. For example, fluvoxamine, a potent CYP1A2 inhibitor, increases duloxetine's AUC and Cmax by 460% and 141%, respectively . This necessitates careful monitoring and potential dose adjustments when duloxetine is coadministered with CYP1A2 inhibitors.
Interactions with Cardiovascular Drugs
Metoprolol
Duloxetine can significantly affect the pharmacokinetics of metoprolol, a beta-blocker metabolized by CYP2D6. Studies have shown that duloxetine increases metoprolol's AUC and Cmax, indicating a potential for increased metoprolol exposure and associated adverse effects . This interaction underscores the need for caution and possible dose adjustments when these drugs are used together.
Acenocoumarol
There is evidence suggesting that duloxetine may enhance the anticoagulant effects of acenocoumarol, leading to a significant decrease in the international normalized ratio (INR) and increasing the risk of bleeding . This interaction highlights the importance of close monitoring of INR levels in patients receiving both medications.
Interactions with Pain Medications
Ibuprofen
Preclinical studies indicate that the combination of duloxetine and ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), can have synergistic effects in reducing inflammatory pain . This suggests potential benefits in pain management, although clinical studies are needed to confirm these findings.
Quetiapine
Duloxetine can also interact with quetiapine, an antipsychotic used in treating major depressive disorder. Pharmacokinetic studies in rats have shown that quetiapine significantly increases the plasma exposure of duloxetine, which could enhance duloxetine's therapeutic and adverse effects . This interaction warrants careful consideration in clinical settings.
Interactions with Functional Foods
Propolis
Propolis, a popular functional food, can significantly increase duloxetine's plasma concentration. Studies have shown that high doses of propolis can increase duloxetine's Cmax and AUC by approximately 20-28%, suggesting a potential for increased duloxetine exposure and associated risks . Patients using both duloxetine and propolis should be monitored for adverse effects.
Conclusion
Duloxetine's interactions with various drugs and functional foods primarily involve its effects on and by the CYP2D6 and CYP1A2 enzymes. These interactions can lead to significant changes in drug exposure, necessitating careful monitoring and potential dose adjustments. Understanding these interactions is essential for optimizing duloxetine therapy and minimizing adverse effects.
Sources and full results
Most relevant research papers on this topic
An Assessment of Drug-Drug Interactions: The Effect of Desvenlafaxine and Duloxetine on the Pharmacokinetics of the CYP2D6 Probe Desipramine in Healthy Subjects
Desvenlafaxine has a minimal impact on desipramine's pharmacokinetics compared to duloxetine, suggesting a lower risk for CYP2D6-mediated drug interactions.
Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.
Duloxetine is an effective treatment for major depressive disorder and diabetic peripheral neuropathic pain, but not for stress urinary incontinence or pain associated with diabetic peripheral neuropathy.
DOI